- Home
- VOXR vs SGHT Comparison
VOXR vs SGHT Comparison
Compare VOXR & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- SGHT
- Stock Information
- Founded
- VOXR 2014
- SGHT 2011
- Country
- VOXR United States
- SGHT United States
- Employees
- VOXR N/A
- SGHT N/A
- Industry
- VOXR Precious Metals
- SGHT Medical Specialities
- Sector
- VOXR Basic Materials
- SGHT Health Care
- Exchange
- VOXR Nasdaq
- SGHT Nasdaq
- Market Cap
- VOXR 168.0M
- SGHT 157.7M
- IPO Year
- VOXR N/A
- SGHT 2021
- Fundamental
- Price
- VOXR $3.33
- SGHT $3.55
- Analyst Decision
- VOXR
- SGHT Buy
- Analyst Count
- VOXR 0
- SGHT 7
- Target Price
- VOXR N/A
- SGHT $3.92
- AVG Volume (30 Days)
- VOXR 191.1K
- SGHT 182.9K
- Earning Date
- VOXR 05-15-2025
- SGHT 05-08-2025
- Dividend Yield
- VOXR 1.50%
- SGHT N/A
- EPS Growth
- VOXR N/A
- SGHT N/A
- EPS
- VOXR N/A
- SGHT N/A
- Revenue
- VOXR $10,845,445.00
- SGHT $78,109,000.00
- Revenue This Year
- VOXR $16.51
- SGHT N/A
- Revenue Next Year
- VOXR $4.60
- SGHT $11.68
- P/E Ratio
- VOXR N/A
- SGHT N/A
- Revenue Growth
- VOXR N/A
- SGHT N/A
- 52 Week Low
- VOXR $1.93
- SGHT $2.03
- 52 Week High
- VOXR $3.57
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- VOXR 56.97
- SGHT 67.57
- Support Level
- VOXR $2.97
- SGHT $3.18
- Resistance Level
- VOXR $3.35
- SGHT $3.26
- Average True Range (ATR)
- VOXR 0.16
- SGHT 0.27
- MACD
- VOXR -0.01
- SGHT 0.04
- Stochastic Oscillator
- VOXR 69.35
- SGHT 89.01
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.